Background: In fluorescein isothiocyanate (FITC)-induced contact hypersensitivity models, dibutyl phthalate has been empirically used as a solvent ingredient. We have demonstrated that dibutyl phthalate has an adjuvant effect through the facilitation of trafficking FITC-presenting dendritic cells (DC) from the skin to draining lymph nodes. Here we investigated the effects of local pretreatment with substances that are capable of desensitizing sensory neurons in the sensitization phase. Methods: Local pretreatment of BALB/c mice with capsaicin (epicutaneous), allyl isothiocyanate (epicutaneous) or a truncated form of calcitonin gene-related peptide (CGRP8–37; intradermal) was performed before contact sensitization to FITC. The ear swelling test was employed to monitor sensitization. The appearance of FITC-presenting CD11c-positive cells in the draining lymph nodes was detected by flow cytometry. Cytokine production in local lymph node cell cultures was determined by ELISA. Results: The ear swelling response was reduced in mice pretreated with capsaicin or allyl isothiocyanate. DC trafficking and maturation (based on the levels of costimulators CD80 and CD86) were inhibited. Interleukin-4 production by local lymph nodes was suppressed with allyl isothiocyanate but not with capsaicin. Pretreatment with CGRP8–37 suppressed sensitization to FITC. Conclusions: Local pretreatment with substances that are capable of desensitizing sensory neurons through the respective transient receptor potential channels suppressed skin sensitization to FITC in a mouse model. This was associated with reduced trafficking and maturation of FITC-presenting DC. A CGRP antagonist also suppressed the sensitization to FITC, suggesting the possible involvement of sensory neurons in sensitization.

Keywords:
Cell trafficking, Dendritic cells, Neuroimmunology, Transient receptor potential channel
1.
Kripke ML, Munn CG, Jeevan A, Tang JM, Bucana C: Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol 1990;145:2833–2838.
2.
Sato K, Imai Y, Irimura T: Contribution of dermal macrophage trafficking in the sensitization phase of contact hypersensitivity. J Immunol 1998;161:6835–6844.
3.
Engeman TM, Gorbachev AV, Gladue RP, Heeger PS, Fairchild RL: Inhibition of functional T cell priming and contact hypersensitivity responses by treatment with anti- secondary lymphoid chemokine antibody during hapten sensitization. J Immunol 2000;164:5207–5214.
4.
Maestroni GJ, Mazzola P: Langerhans cells β2-adrenoceptors: role in migration, cytokine production, Th priming and contact hypersensitivity. J Neuroimmunol 2003;144:91–99.
5.
Sato K, Imai Y, Higashi N, Kumamoto Y, Onami TM, Hedrick SM, Irimura T: Lack of antigen-specific tissue remodeling in mice deficient in the macrophage galactose-type calcium-type lectin 1/CD301a. Blood 2005;106:207–215.
6.
Chun KH, Imai Y, Higashi N, Irimura T: Migration of dermal cells expressing a macrophage C-type lectin during the sensitization phase of delayed-type hypersensitivity. J Leukoc Biol 2000;68:471–478.
7.
Sawynok J: Topical and peripherally acting analgesics. Pharmacol Rev 2003;55:1–20.
8.
Clapham DE: TRP channels as cellular sensors. Nature 2003;426:517–524.
9.
Pedersen SF, Owsianik G, Nilius B: TRP channels: an overview. Cell Calcium 2005;38:233–252.
10.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816–824.
11.
Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, Julius D: Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004;427:260–265.
12.
Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A: ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003;112:819–829.
13.
Beresford L, Orange O, Bell EB, Miyan JA: Nerve fibres are required to evoke a contact sensitivity response in mice. Immunology 2004;111:118–125.
14.
Inoue H, Asaka T, Nagata N, Koshihara Y: Mechanism of mustard oil-induced skin inflammation in mice. Eur J Pharmacol 1997;333:231–240.
15.
Tang A, Judge TA, Nickoloff BJ, Turka LA: Suppression of murine allergic contact dermatitis by CTLA4Ig: tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J Immunol 1996;157:117–125.
16.
Takeshita K, Yamasaki T, Akira S, Gantner F, Bacon KB: Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse. Int Immunol 2004;16:685–695.
17.
Imai Y, Kondo A, Iizuka H, Maruyama T, Kurohane K: Effects of phthalate esters on the sensitization phase of contact hypersensitivity induced by fluorescein isothiocyanate. Clin Exp Allergy 2006;36:1462–1468.
18.
Dearman RJ, Moussavi A, Kemeny DM, Kimber I: Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens. Immunology 1996;89:502–510.
19.
Dearman RJ, Kimber I: Role of CD4+ T helper 2-type cells in cutaneous inflammatory responses induced by fluorescein isothiocyanate. Immunology 2000;101:442–451.
20.
Banvolgyi A, Pozsgai G, Brain SD, Helyes ZS, Szolcsanyi J, Ghosh M, Melegh B, Pinter E: Mustard oil induces a transient receptor potential vanilloid 1 receptor-independent neurogenic inflammation and a non-neurogenic cellular inflammatory component in mice. Neuroscience 2004;125:449–459.
21.
Veronesi B, Williams WC, Smialowicz RJ, Sailstad DM, Doerfler D, Selgrade MJ: Neuropeptide denervation alters both the elicitation and induction phases of contact hypersensitivity in mice. Toxicol Appl Pharmacol 1998;153:243–249.
22.
Banvolgyi A, Palinkas L, Berki T, Clark N, Grant AD, Helyes Z, Pozsgai G, Szolcsanyi J, Brain SD, Pinter E: Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. J Neuroimmunol 2005;169:86–96.
23.
Stander S, Moormann C, Schumacher M, Buddenkotte J, Artuc M, Shpacovitch V, Brzoska T, Lippert U, Henz BM, Luger TA, Metze D, Steinhoff M: Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004;13:129–139.
24.
Saunders CI, Kunde DA, Crawford A, Geraghty DP: Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol Immunol 2007;44:1429–1435.
25.
Basu S, Srivastava P: Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells. Proc Natl Acad Sci USA 2005;102:5120–5125.
26.
O’Connell PJ, Pingle SC, Ahern GP: Dendritic cells do not transduce inflammatory stimuli via the capsaicin receptor TRPV1. FEBS Lett 2005;579:5135–5139.
27.
Seiffert K, Hosoi J, Torii H, Ozawa H, Ding W, Campton K, Wagner JA, Granstein RD: Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol 2002;168:6128–6135.
28.
Torii H, Tamaki K, Granstein RD: The effect of neuropeptides/hormones on Langerhans cells. J Dermatol Sci 1998;20:21–28.
29.
Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD: Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993;363:159–163.
30.
Marriott I, Mason MJ, Elhofy A, Bost KL: Substance P activates NF-κB independent of elevations in intracellular calcium in murine macrophages and dendritic cells. J Neuroimmunol 2000;102:163–171.
31.
Carucci JA, Ignatius R, Wei Y, Cypess AM, Schaer DA, Pope M, Steinman RM, Mojsov S: Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol 2000;164:3494–3499.
32.
Asahina A, Moro O, Hosoi J, Lerner EA, Xu S, Takashima A, Granstein RD: Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects. Proc Natl Acad Sci USA 1995;92:8323–8327.
33.
Kodali S, Ding W, Huang J, Seiffert K, Wagner JA, Granstein RD: Vasoactive intestinal peptide modulates Langerhans cell immune function. J Immunol 2004;173:6082–6088.
34.
Delgado M, Gonzalez-Rey E, Ganea D: The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005;175:7311–7324.
35.
Dunzendorfer S, Kaser A, Meierhofer C, Tilg H, Wiedermann CJ: Cutting edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J Immunol 2001;166:2167–2172.
36.
Kaneider NC, Kaser A, Dunzendorfer S, Tilg H, Patsch JR, Wiedermann CJ: Neurokinin-1 receptor interacts with PrP106–126-induced dendritic cell migration and maturation. J Neuroimmunol 2005;158:153–158.
37.
Delgado M, Leceta J, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 2002;16:1844–1846.
38.
Lambrecht BN: Immunologists getting nervous: neuropeptides, dendritic cells and T cell activation. Respir Res 2001;2:133–138.
39.
Takeguchi N, Nishimura Y, Watanabe T, Mori Y, Morii M: A pungent ingredient of mustard, allylisothiocyanate, inhibits (H+ + K+)-ATPase. Biochem Biophys Res Commun 1983;112:464–468.
40.
Gomes RN, Castro-Faria-Neto HC, Bozza PT, Soares MB, Shoemaker CB, David JR, Bozza MT: Calcitonin gene-related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. Shock 2005;24:590–594.
41.
Asahina A, Hosoi J, Beissert S, Stratigos A, Granstein RD: Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J Immunol 1995;154:3056–3061.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.